Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers

Konstantinos Venetis[1,2], Elham Sajjadi[1], Svasti Haricharan[3], Nicola Fusco[1,4]

[1]Division of Pathology, IRCCS European Institute of Oncology (IEO), Milan, Italy; [2]Phd Program in Translational Medicine, University of Milan, Milan, Italy; [3]Department of Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA; [4]Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

Correspondence to: Prof. Nicola Fusco, MD. Division of Pathology, IRCCS European Institute of Oncology (IEO), University of Milan, Via Giuseppe Ripamonti 435, 20141 Milan, Italy. Email: nicola.fusco@unimi.it.

The treatment of breast cancer has progressed amazingly during the past three decades but a relatively high proportion of patients still experience resistance to pharmacotherapy (i.e., endocrine therapy, chemotherapy, and HER2-directed antibody-drugs) (1,2). Lately, two immune checkpoint inhibitors have been approved in several countries for the treatment of breast cancer. Specifically, atezolizumab (Tecentriq®, Genentech Inc, South San Francisco, CA, USA), an anti-programmed death-ligand 1 (PD-L1) drug, and pembrolizumab (Keytruda®, Merck & Co. Inc., Kenilworth, NJ, USA), that blocks PD-L1 receptor programmed cell death protein 1 (PD-1). Ongoing phase II and III trials are expected to lead to more approvals in different clinical settings.

At present, breast cancer immunotherapy is biomarker-based (3). In unresectable locally advanced or metastatic triple-negative breast cancers (TNBC), only cases in which the tumor-infiltrating immune cells express PD-L1 in ≥1% of the tumor area can be treated with atezolizumab (4). The VENTANA PD-L1 (SP142) Assay (Roche Tissue Diagnostics, Tucson, AZ, USA) comes as a companion diagnostic (CDx) test for this analysis. Results of KEYNOTE-355 recently presented at ASCO 2020 revealed progression-free survival benefits of pembrolizumab plus chemotherapy in high PD-L1 expression TNBC. However, this analysis is not yet part of the everyday in clinical practice. On the other hand, the Food and

Drug Administration (FDA) approved pembrolizumab in all refractory advanced solid tumors with mismatch repair (MMR) deficiency and/or high levels of microsatellite instability (MSI) (5). Regrettably, our knowledge on the specific biology of MMR deficiency in breast cancer is limited, both in terms of identifying relative contributions of this system to patient outcomes and in understanding the role of cellular localization of MMR proteins to cancer phenotypes.

Genomic scars in the MMR system occur at relatively low frequency in breast cancer and are reported in approximately 2% of cases. However, this subject is controversial in literature given the lack of CDx and/or tumor-specific guidelines for MMR analysis (6-11). Hence, MMR data in breast cancer may vary according to the testing method employed, such as direct sequencing of microsatellite markers, next-generation sequencing (NGS), and immunohistochemistry (IHC) for the four MMR proteins (*Table 1*). To date, a constellation of locally developed tests can be found (12). These are generally modeled on those approved for colorectal and endometrial carcinomas, where MSI is more frequent (15% and 20–30%, respectively) than in breast cancer (13,14). It needs to be highlighted that in these types of cancer, MMR and MSI testings were not standardized to inform immunotherapy decisions but for the screening of Lynch syndrome, an inherited disorder caused by germline defects in the MMR systems (15).

The mechanisms underpinning the possible susceptibility

Table 1 Studies on mismatch repair (MMR) status and breast cancer

Authors	Ref.	Year	Testing method	Nr. of patients	dMMR (%)
Cheng *et al.*	(6)	2020	IHC	1,635	1.9
Lopez *et al.*	(7)	2020	IHC	608	13.3
Fusco *et al.*	(8)	2018	IHC & MSI	444	17
Lee *et al.*	(9)	2019	Sanger Sequencing, IHC, MSI	94	3.2
Le *et al.*	(10)	2017	NGS	N/A	<2
Davies *et al.*	(11)	2017	WGS	640	1.7

dMMR, MMR deficiency; IHC, immunohistochemistry; MSI, microsatellite instability; NGS, next-generation sequencing; WGS, whole-genome sequencing.


Figure 1 Frequency and patterns of mismatch repair protein loss across 31 mismatch repair deficient breast cancers from the British Columbia cohort.

of MMR-deficient breast cancers to immune-checkpoint blockade is not trivial. Dysfunction in the MMR system may result in a hypermutator state, with subsequent neo-antigen generation by the neoplastic cells and activation of the adaptive immune response (16). On the other hand, MMR defects in breast cancer induce an increase in tumor mutation burden (TMB) that is many orders of magnitude lower than that seen in archetypal Lynch syndrome spectrum cancers (17,18). Hence, there may be essential differences in how MMR functions in breast compared to other cancer sites.

Clinicopathologic features of MMR-deficient breast cancers

In this scenario, a recently published study of Cheng *et al.* (6)

has provided important insights. The Authors profiled the expression of the four key MMR proteins [i.e., mutL homolog 1 (MLH1), PMS1 Homolog 2 (PMS2), mutS homolog 2 (MSH2), and mutS homolog 6 (MSH6)] by IHC on a large series of breast cancer patients. Their main objective was to better understand the clinical meaning of MMR deficiency in breast cancer, particularly in terms of long-term outcomes. Out of 3,992 tumors embedded in tissue microarrays, 1,635 (41%) cases were interpretable. Among them, 31 (2%) breast cancers showed the loss of nuclear staining for at least one of the MMR proteins, being identified as MMR deficient. Unlike endometrial and colorectal cancers, the majority of patients from the study of Cheng *et al.* presented with a single protein loss (n=25, 81%) while the remaining 6 (19%) cases had pair loss (*Figure 1*). Interestingly, the MutLα complex, which is composed of MLH1 and PMS2, was more targeted by alterations than MutSα (i.e., MSH2 and MSH6). The highest frequency of MMR deficiency was observed in Luminal breast cancers (n=22, 71%), as previously observed (8). The authors reported a specific correlation with high grade, low progesterone receptor (PR) expression, and high tumor-infiltrating lymphocytes (TILs) counts. However, the low proportion of MMR deficient samples precludes a conclusive understanding of the incidence rate variance between specific subclasses of patients. It could be argued that the connection between MMR deficiency and high histologic grade may be due to a higher TMB (19). However, mutations in known oncogenic drivers are not statistically enriched in MMR-defective relative to MMR-proficient breast cancers (11).

The overall chemical integrity of the MMR system has been related to patients' prognosis in several cancer types (20). Cheng *et al.* showed a non-significant decrease in the

4062

Venetis et al. Mismatch repair testing in breast cancer

overall survival and breast cancer disease-specific survival across all breast cancer types. However, the analyses based on treatment showed that estrogen receptor (ER)-positive patients with MMR deficiency who received tamoxifen as adjuvant systemic therapy had worse survival. Of note, dysfunctions of the MutLα complex are related to resistance phenomena to all classes of endocrine therapy in breast cancer (21-23). This observation also argues against high TMB caused by MMR deficiency as the driver of poor outcomes, since MMR deficiency increases mutational load across breast cancer subtypes, and yet associates with poor outcomes only in ER+ patients (24). All these diverse observations highlight the importance of MMR testing/ screening in breast cancer patients.

Real-life challenges in MMR clinical testing

Investigating MMR-deficiencies in breast cancer is not an easy task. Several issues in MMR clinical testing are related to the limitations of the existing methods and the absence of CDx and/or tumor-specific guidelines. Despite immunohistochemistry of the four MMR proteins and MSI testing being widely applied, these tests are not interchangeable in breast cancer since MMR protein loss is more commonly detected than MSI (8). Of note, not all MMR proteins equally impact either mutation load or MSI when defective. It remains to be determined how much the MMR status assessment is troubled by technical artifacts and/or intra-tumor heterogeneity phenomena. On the other hand, accumulating evidence on the significant prognostic value of MMR IHC in breast cancer seems to suggest the clinical validity of this test (6-8). To this end, specific antibody clones, CDx, and/or interpretation guidelines are warranted. Methylation-specific PCR for testing hypermethylation of *MLH1* promoter akin somatic variant screening through NGS is usually performed as verification methods (12). However, in breast cancer, a tumor-specific panel of genes would be required to test any possible association of MMR deficiency with other clinically actionable genes. Finally, TMB is another emerging biomarker (25). Increased TMB was found in tumors with defects in the MMR system, thus, it could be used as a surrogate diagnostic assay. Unfortunately, TMB analysis is neither time nor cost-effective while it may prove misleading in cases of unsuitable NGS panels. Also, as in the case of MSI, TMB does not provide insight into which individual MMR protein is defective in a given patient tumor. Finally, there are no guidelines on the genes

to include in the TMB count. Hence, whole-exome TMB-high tumors may not be related to MMR deficiency and/or worse prognosis (18). All these methods represent candidate tools for MMR testing in breast cancer, but they need to be profoundly tested in order to overcome existing limitations and make routine testing feasible.

The study of Cheng *et al.* has added great value to this topic, mostly by assessing the clinical meaning of MMR deficiency in the largest cohort of breast cancer patients thus far, while it brought to light several disadvantages of existing techniques. Due to the high degree of intratumor heterogeneity that characterizes breast cancer, sampling and analyzing different topographic areas of the same tumor could be more reliable. This intratumor heterogeneity is also specifically true for MLH1 expression, where mutational analyses demonstrate that *MLH1* mutations are not founders but only occur in specific subclonal populations. It would be helpful for IHC analysis to be combined with genomic analysis in order to increase the sensitivity and specificity.

At the moment, only a few studies have tried to investigate MMR-deficiency in breast cancer, but their results are not in consensus. Considering the limitations of these studies, it is evident that locally developed methods present disadvantages and inadequate reproducibility. Therefore, tumor-specific guidelines, companion and complementary diagnostics, as well as surrogate biomarkers, are necessary for a targeted MMR status assessment in breast cancer. It is fair to conclude that improvements in MMR testing are necessary in order to enable its application in clinical practice.

Acknowledgments

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi. org/10.21037/tcr-20-1852). SH has a patent "MutL loss predicts sensitivity to CDK4/6 inhibitors in cancer" pending to Baylor College of Medicine. NF reports personal fees from Merck Sharp & Dohme (MSD) and Boehringer Ingelheim, outside the submitted work. In addition, NF has a patent "PTEN IHC as a predictor of

mismatch repair status in breast cancer" pending to Italian Patent and Trademark Office. The other authors have no conflict of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Lei JT, Anurag M, Haricharan S, et al. Endocrine therapy resistance: new insights. Breast 2019;48 Suppl 1:S26-S30.
2. Grizzi G, Ghidini M, Botticelli A, et al. Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. Cancer Manag Res 2020;12:675-86.
3. Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res 2018;24:511-20.
4. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379:2108-21.
5. Marcus L, Lemery SJ, Keegan P, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res 2019;25:3753-8.
6. Cheng AS, Leung SCY, Gao D, et al. Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Res Treat. 2020;179:3-10.
7. Lopez G, Noale M, Corti C, et al. PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences 2020;21:1461.
8. Fusco N, Lopez G, Corti C, et al. Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability.

9. Lee SE, Lee HS, Kim KY, et al. High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer. Sci Rep 2019;9:10966.
10. Le DT, Durham JN, Smith KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-13.
11. Davies H, Morganella S, Purdie CA, et al. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. Cancer Res 2017;77:4755-62.
12. Corti C, Sajjadi E, Fusco N. Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All? Adv Anat Pathol 2019;26:270-9.
13. Stelloo E, Jansen AML, Osse EM, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol 2017;28:96-102.
14. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 2010;7:174-7.
15. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014;146:643-6.e8.
16. Subbiah V, Kurzrock R. The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. Oncologist 2019;24:1-3.
17. Haricharan S, Bainbridge MN, Scheet P, et al. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat 2014;146:211-20.
18. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
19. Budczies J, Bockmayr M, Denkert C, et al. Classical pathology and mutational load of breast cancer – integration of two worlds. J Pathol Clin Res 2015;1:225-38.
20. Germano G, Amirouchene-Angelozzi N, Rospo G, et al. The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. Cancer Discov 2018;8:1518-28.
21. Haricharan S, Punturi N, Singh P, et al. Loss of MutL disrupts Chk2-dependent cell cycle control through CDK4/6 to promote intrinsic endocrine therapy resistance in primary breast cancer. Cancer Discov 2017;7:1168-83.
22. Anurag M, Punturi N, Hoog J, et al. Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance

JNCI Cancer Spectr 2018;2:pky056.

Drivers. Clin Cancer Res 2018;24:4887-99.

23. Anurag M, Ellis MJ, Haricharan S. DNA damage repair defects as a new class of endocrine treatment resistance driver. Oncotarget 2018;9:36252-3.

24. Lopez G, Costanza J, Colleoni M, et al. Molecular Insights into the Classification of Luminal Breast Cancers:

The Genomic Heterogeneity of Progesterone-Negative Tumors. Int J Mol Sci 2019;20.

25. Pagni F, Guerini-Rocco E, Schultheis AM, et al. Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. Int J Mol Sci 2019;20:5452.